Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Stability of Furosemide 5 mg/mL in Polypropylene Syringes

Author(s):  van der Schaar JAJ, Grouls R, Franssen EJF, Crul M

Issue:  Sep/Oct 2019 - Volume 23, Number 5
View All Articles in Issue

Page(s):  414-417

Stability of Furosemide 5 mg/mL in Polypropylene Syringes Page 1
Stability of Furosemide 5 mg/mL in Polypropylene Syringes Page 2
Stability of Furosemide 5 mg/mL in Polypropylene Syringes Page 3
Stability of Furosemide 5 mg/mL in Polypropylene Syringes Page 4

Download in electronic PDF format for $75

Abstract:  Furosemide parenteral solutions are routinely used in our hospital. However, the stability in transparent syringes is unknown. In this study, transparent polypropylene syringes were filled with 8 mL and 50 mL of furosemide 5-mg/mL solution. The furosemide was analyzed by high-performance liquid chromatography and assays were performed up to 35 days of storage of the syringes at 4°C protected from light, plus 24 hours at 20°C exposed to daylight. In addition, the appearance and pH of the solutions were determined. A microbiological assay using tryptic soy broth was also performed. Both types of syringes remained colorless, clear, and free from visible particles throughout the study period. The pH did not change, and concentrations remained between 95% and 105% of the stated concentration. None of the syringes filled with culture media exhibited bacterial or fungal growth. In conclusion, ready-to-administer furosemide 5-mg/mL, 8-mL, and 50-mL polypropylene syringes are stable for up to 35 days when stored in a refrigerator at 4°C protected from light, plus 24 hours at 20°C unprotected from light. These results allow maximum storage time in stock and the ability of 24-hour continuous infusion at ambient room temperature without protecting the syringe against light.

Related Keywords: furosemide, short-acting loop diuretic, diuresis, acute pulmonary edema, edema, congestive heart failure, renal impairment, hepatic disease, liver dysfunction, ascites, hospital pharmacy, ready-to-administer batch production, parenteral administration, aseptic formulations, compounded sterile preparations, continuous infusion, photodegradation, transparent polypropylene syringes, chemical stability, physical stability, microbial stability, bacterial contamination

Related Categories: PARENTERALS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, CARDIOLOGY, HOSPITAL PHARMACY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Stability of Furosemide 5 mg/mL in Polypropylene Syringes
van der Schaar JAJ
, Grouls R, Franssen EJF, Crul M
Sep/Oct 2019
Pg. 414-417

Treating Canine Hepatic Disease
Davidson Gigi S
May/Jun 2003
Pg. 188-191

Furosemide 10-mg/mL Oral Suspension
Allen Loyd V Jr
Mar/Apr 2017
Pg. 148

Furosemide 5-mg/mL Oral Suspension
Allen Loyd V Jr
Jul/Aug 2022
Pg. 321-322

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Dexamethasone and Furosemide Injection
Allen Loyd V Jr
Jul/Aug 2009
Pg. 335

Long-term Physiochemical Stability of Concentrated Solutions of Salbutamol (Albuterol) in Polypropylene Syringes for Use in the Intensive Care Unit and in Obstetrics
Lardinois Benjamin
, Baltzis Alexandre, Delcave Charlotte, Soumoy Laura, Jamart Jacques, Bihin Benoît, Hecq Jean-Daniel, Galanti Laurence
Sep/Oct 2019
Pg. 434-437

Congestive Heart Failure and Other Medical Facts About Ferrets; Scout's Story: A Case Report on Treating Congestive Heart Failure in a Ferret
Williams LaVonn A
, Riley Kari
Sep/Oct 2009
Pg. 367-371

Alcohol-free Extemporaneous Formulations of Furosemide Are Chemically and Physically Stable in Ora-Blend Products for 30 Days
Svirskis Darren
, Jaffer Johaina, Agarwal Priyanka, Khan Ayeshah, Kaur Jaskarn, Cheng Alan, Hanning Sara
May/Jun 2020
Pg. 246-251

Furosemide 10-mg/mL Injection
Allen Loyd V Jr
Mar/Apr 2012
Pg. 158

Bumetanide 0.25-mg/mL Injection
Allen Loyd V Jr
Jan/Feb 2014
Pg. 61

Spironolactone 5 mg/mL in SuspendIt Oral Suspension
Allen Loyd V Jr
Nov/Dec 2017
Pg. 496

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Chemical Stability of Furosemide in Minibags and Polypropylene Syringes
Donnelly Ronald F
Nov/Dec 2002
Pg. 468-470

Intravenous Physical Compatibility of Heparin Sodium and Furosemide
Maktabi Briana
, Howard Mitchell S, Baki Gabriella, Churchwell Mariann D
Nov/Dec 2022
Pg. 522-526

Basics of Compounding for Cough
Allen Loyd V Jr
Nov/Dec 2004
Pg. 462-465

Coenzyme Q10 Supplementation in the Treatment of Heart Disease
Bramwell Bethany L
Mar/Apr 2010
Pg. 108-111

Bumetanide 0.5-mg, 1-mg, or 2-mg Capsules
Allen Loyd V Jr
May/Jun 2014
Pg. 233

Torsemide 5 mg/mL in Ora-Plus:Ora-Sweet Suspension
Allen Loyd V Jr
Sep/Oct 2018
Pg. 411

Stability of Nitroglyercin 100 mcg/mL Stored in Polypropylene Syringes
McCluskey Susan V
, Vu Nicole, Rueter John
Nov/Dec 2013
Pg. 515-519

Return to Top